39 results about "Immunohis tochemistry" patented technology

The invention discloses an anti-soluble transferrin receptor monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibody detection. According to the antibody, an L101-F760 amino acid sequence of human TfR protein is used as an immunogen, specific screening of B cells, reverse RNA (Ribonucleic Acid) into cDNA (Complementary Deoxyribose Nucleic Acid) through RT-PCR (Reverse Transcription-Polymerase Chain Reaction), then homologous recombination is performed to construct heavy and light chain vectors, and finally multiple rounds of screening are performed to obtain the purified sTfR monoclonal antibody, so that the sTfR protein can be specifically recognized, and the antibody has the advantages of high specificity and high sensitivity and can be widely applied to the field of immunotherapy. The natural sTfR protein in human serum can be recognized. The kit is applied to the detection and screening fields of immunohistochemistry, immunofluorescence chemistry, western blot, co-immunoprecipitation, indirect ELISA, flow cytometry and the like, especially has low background and no interference of non-specific binding impure protein during immunohistochemistry detection, can obtain more accurate detection and evaluation results, avoids interference of false positive and false negative, and has high detection accuracy. The method has great application value in the aspects of basic scientific research and clinical pathology detection.

The invention relates to the technical field of medical imaging, in particular to a breast cancer tissue HER2 automatic scoring method and device based on a characteristic curve, and the method comprises the steps: carrying out the reading operation of a full-slice image of immunohistochemical staining; extracting a target region of interest of the full slice image; slicing and screening the target region of interest to obtain a plurality of image slices; calculating a percentage-saturation characteristic curve of each image slice, and extracting characteristic information of the percentage-saturation characteristic curve; based on the feature information of the percentage-saturation feature curve, performing preliminary HER2 scoring on each image slice in combination with a rule base and a logistic regression classification algorithm; and integrating the scoring results of the image slices, and outputting a final HER2 score and a characteristic curve visualization graph. According to the method, the feature curve is combined with the rule base and the logistic regression classification algorithm, so that the objectivity of HER2 scoring is improved, and the problems of subjectivity and low efficiency of manual evaluation are reduced.

The present disclosure provides antibodies, including but not limited to monoclonal antibodies, capable of specifically binding the human PAX8 protein. Also provided are nucleic acids encoding the anti-PAX8 antibodies described herein, as well as expression vectors comprising these nucleic acids, host cells transformed with the expression vectors comprising the nucleic acids encoding the anti-PAX8 antibodies, and methods of making the antibodies. The anti-PAX8 antibodies described herein are useful for immunohistochemical detection of human PAX8 protein in tissue samples.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

The application discloses application of YW2301 in preparation of a medicine for resisting Burkitt lymphoma, utilizes CCK8 cell activity experiment to detect the inhibition ability of YW2301 on Raji and CA46 cell proliferation, constructs a NON / SCID subcutaneous transplantation tumor model by using a Raji cell line, evaluates the therapeutic significance of YW2301 on Burkitt lymphoma, YW2301 can effectively inhibit the tumorigenicity of Burkitt lymphoma cells and the growth speed of the transplantation tumor, and adopts immunohistochemical staining to detect the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma transplantation tumor tissue section, YW2301 can effectively down-regulate the ALDH18A1 and c-Myc protein expression in a Burkitt lymphoma tissue, and further proves that YW2301 can be used as a candidate small molecule for targeted treatment of Burkitt lymphoma.

A method for pre-treatment identification of cancer patients that respond to anti-CLEVER-1 therapy comprising an administration of an agent capable of binding to CLEVER-1 in a patient. In the method, the presence of CLEVER-1 expressing cells is detected in a tumor sample obtained from a cancer patient, by immunohistochemistry staining by a mouse monoclonal IgG2a kappa STAB-1 antibody (clone 4G9), and a percentage of intra-tumoral CLEVER-1 expressing cells from the total amount of viable intra-tumoral cells present in the stained sample is calculated. A tumor sample which shows substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

The present application relates to the technical field of biology, and particularly discloses a kind of tyrosine iodination modified PP2A protein monoclonal antibody, preparation method and application.The present application is prepared by tyrosine iodination modified PP2A protein antigen peptide, rabbit is immunized to prepare monoclonal antibody, and is selected by phage display technology, expression vector amplification and ELISA screening, finally obtains a strain of monoclonal antibody R004 that can effectively recognize target.The antibody shows good sensitivity and specificity in immunohistochemistry, cell immunofluorescence and protein immunoblotting.The monoclonal antibody screened in the present application can be used in the detection of tyrosine iodination modification of PP2A protein catalytic subunit 307, and provides support for tumor diagnosis, anti-tumor and neurological disease drug research and development.

A laboratory immunohistochemical staining slide fixing and auxiliary operation apparatus, comprising an immunohistochemical staining slide fixing apparatus (1), a storage box (5), and a dedicated filter box for coverslipping (6). The immunohistochemical staining slide fixing apparatus (1) comprises a slide grasping spring (11), a first handle (12) and a second handle (13), one end of the first and second handles (12, 13) being fixed to two sides of the slide grasping spring (11), respectively, and the other ends each being bent inward to form first and second gripping parts (14, 15). By means of squeezing the handles (12, 13) to drive the top of the slide grasping spring (11) to arch open, multiple staining slides (2) can be inserted and positioned on the slide grasping spring (11); releasing the spring (11) can clamp and fix the slides (2) for subsequent batch immunohistochemical staining operations, such as staining and washing, significantly improving experiment efficiency. The storage box (5) enables centralized storage of multiple slide fixing apparatuses (1), preventing small fixing apparatuses (1) from being lost due to random placement, and reducing laboratory losses. The dedicated filter box for coverslipping (6) is used to place a slide (2) to be coverslipped on a filter mesh thereof for coverslipping processing, allowing residual xylene on the slide (2) to be centrally recovered, and thereby improving laboratory environmental safety and the personal safety of operators.

w The invention discloses a detection method for predicting efficacy and prognosis of immunotherapy for small cell lung cancer based on ATAD2 expression, and relates to the technical fields of molecular biology and cancer treatment. The method comprises the following steps: extracting a tumor tissue sample of a small cell lung cancer patient through surgical resection; Detecting the tumor tissue sample to obtain ATAD2 expression level, wherein the detection adopts an immunohistochemical staining method. According to the invention, the expression level of ATAD2 in tumor tissues of small cell lung cancer is quantitatively evaluated by immunohistochemical detection technology, and the molecular marker information is systematically correlated with the clinical and pathological characteristics of patients by combining Cox regression analysis and Logistic regression analysis, so that the comprehensive prediction of immunotherapy efficacy and patient survival time is realized.

This invention discloses an anti-ERBB2 monoclonal antibody, its preparation method, and its applications, belonging to the field of biomedical technology. This anti-ERBB2 monoclonal antibody uses the intracellular domain of the human ERBB2 protein as an immunogen and is obtained through animal immunization, B cell screening, gene cloning, and recombinant expression techniques. It can specifically recognize the human ERBB2 protein, exhibiting high affinity and high specificity, and can recognize both native and denatured ERBB2 proteins. This monoclonal antibody can be applied in immunohistochemistry, immunofluorescence, Western blotting (WB), flow cytometry, ELISA detection, and tumor targeted therapy. Experimental results show that this antibody has low background and no non-specific binding, accurately detecting ERBB2-overexpressing tumor cells and tissues, and has significant application value in the diagnosis, prognostic assessment, and targeted therapy of ERBB2-related diseases such as breast cancer.

The application relates to the field of health assessment, and particularly discloses a ZNF281-based gastric cancer prognosis value evaluation system, which comprises a ZNF281 expression quantification module, which is used for detecting the protein / RNA expression level of ZNF281 in tumor tissue through immunohistochemistry, real-time fluorescent quantitative PCR or Western blot technology; a stemness feature and signal path analysis module, which is used for acquiring the protein expression or cell positive rate of stemness genes CD44 and SOX9; then evaluating the activation state of an IL6 / JAK / STAT3 path, including Western blot detection of a p-STAT3 / STAT3 ratio, ELISA determination of IL6 and CXCL5 cytokine levels; then analyzing the cancer-associated fibroblast infiltration in a tumor microenvironment, quantifying the CAF density through alpha-SMA immunofluorescence staining, and combining single-cell sequencing analysis of the interaction strength of a CXCL5 / CXCR2 signal shaft. The technical scheme of the application can integrate the expression amount of ZNF281, signal path activity and clinical pathological data, and precisely stratify the chemotherapy sensitivity and prognosis of gastric cancer patients.

The invention discloses an environment-friendly biological tissue sample preparation sleeve solution and application thereof, and belongs to the technical field of application of pathological reagents in the pathology department. In order to solve the technical problems that in the prior art, in the tissue fixing and tissue wax block preparation process, the fixing effect is not ideal, fixing liquid and transparent liquid pollute the environment and harm human health, dehydration liquid is not thorough in dehydration, subsequent wax dipping liquid permeation is affected, wax blocks cannot be sliced, and the environment is polluted. The invention provides an environment-friendly biological tissue sample preparation set solution and application thereof, the preparation set solution is composed of a stationary solution, a dehydration solution and a transparent solution, and the stationary solution is composed of 40-70 parts of a protein fixing agent, 1-10 parts of a preservative, 1-5 parts of an osmotic pressure regulator, 2-5 parts of a wetting agent, 0.1-0.5 part of an antioxidant and 15-45 parts of purified water. The prepared sleeve solution can be applied to pathological histology and animal and plant specimen preparation, including conventional pathological diagnosis, immunohistochemical diagnosis technology, molecular biological diagnosis technology and the like.

The invention provides biomarkers, methods involving their use, and a diagnostic kit that enables the distinction between muscle-invasive bladder cancer (MIBC) and non-muscle- invasive bladder cancer (NMIBC) which represents a critical step in the diagnosis and treatment of bladder cancer. This kit, based on widely used and cost-effective immunohistochemistry (IHC) techniques in pathology practice, comprises an effective biomarker panel for distinguishing between MIBC and NMIBC. This invention is suitable for routine use in clinical pathology practice, enabling better guidance of patient treatment processes and more accurate determination of disease progression.

A method for pre-treatment identification of cancer patients that respond to anti-CLEVER-1 therapy comprising an administration of an agent capable of binding to CLEVER-1 in a patient. In the method. the presence of PD-L1 expressing cells and CLEVER-1 expressing cells is detected in a tumor sample obtained from a cancer patient. by immunohistochemistry staining by a PD-L1 specific antibody and a mouse monoclonal lgG2a kappa STAB-1 antibody (clone 4G9), and then a percentage of PD-L1 expressing cells from the total amount of viable cells present in the stained sample, and a percentage of intra-tumoral CLEVER-1 expressing cells from the total amount of viable intra-tumoral cells present in the stained sample. is calculated. A tumor sample which shows low percentage of PD-L1 expressing cells or not comprising PD-L1 expressing cells together with substantial percentage of CLEVER-1 expressing intra-tumoral cells is an indication that the cancer patient is responsive to the anti-CLEVER-1 therapy.

This invention belongs to the field of biotechnology, specifically relating to a recombinant monoclonal antibody against Ki-67, its preparation method, and its applications. The recombinant monoclonal antibody against Ki-67 includes a heavy chain variable region and a light chain variable region; the heavy chain variable region includes the amino acid sequence shown in SEQ ID NO.3; and the light chain variable region includes the amino acid sequence shown in SEQ ID NO.4. This invention utilizes hybridoma technology to prepare a mouse anti-human Ki-67 recombinant monoclonal antibody. This recombinant antibody has a well-defined structure, high titer, and better stability, effectively solving the problems existing in traditional antibody preparation. It can be applied in detection and screening fields such as immunohistochemistry, indirect ELISA, antibody chip preparation, and immunofluorescence, facilitating accurate assessment and detection results.

Provided is a fluorescent compound for labeling a biomaterial having the following Chemical Formula 1:In Chemical Formula 1 above, n is an integer of 1 to 6; X1 and X2 are the same as or different from each other, and each independently selected from H, SO3− and SO3H; R1 and R2 are the same as each other or each independently selected from C1-7 alkyl, substituted or unsubstituted C8-20 alkyl, —(CH2)m1SO3−, —(CH2)m2SO3H, andm1 is an integer of 1 to 7, m2 is an integer of 1 to 7; p1 is an integer of 1 to 10; r1 is an integer of 1 to 10; and Y1 is selected from H, —OH, halogen ando1 is an integer of 1 to 10.

The invention discloses a tumor-retina antigen and application thereof, and relates to the field of breast cancer treatment. The method comprises the following steps: firstly, analyzing transcriptome data and immunohistochemical staining results of a human body, and screening out PDE6G protein which is highly expressed only in normal retina tissues and breast cancer cells of the human body; then, the protein is used as an antigen, a corresponding mRNA vaccine is designed and prepared, and the function and the biological safety of the vaccine are verified on the aspects of cells, tissues and organs. In conclusion, a new target spot and a new mRNA vaccine are provided for treatment of the breast cancer, a theoretical basis is laid for diversified treatment of the breast cancer, and meanwhile, the target spot and the mRNA vaccine have huge application prospects.

In another embodiment, an immunohistochemistry (IHC) method is provided for reproducibly determining and scoring the level of expression of the protein Melanoma Associated Antigen Gene-A4 (MAGE-A4) in tissue samples. In another embodiment, a method is provided for diagnosing, treating, or ameliorating cancer or tumor, or assessing the risk of recurrence, using an IHC method as provided herein. In another embodiment, a kit is provided that includes components and instructions for carrying out a method as provided herein. The present application describes methods for scoring MAGE-A4 expression and using the score as a companion or complementary diagnostic, or for treating or ameliorating cancer or tumor.

In alternative embodiments, provided are chimeric, synthetic or recombinant anti-human ICOS protein or polypeptide (also called inducible T-cell co-stimulator, or Cluster of Differentiation-278, or CD278) antibodies (Abs), including products of manufacture and kits comprising them, and methods for making and using them, including for example their use in the detection or diagnosis, and treatment, of a cancer, or other diseases or conditions involving expression of ICOS. In alternative embodiments, anti-ICOS proteins (for example, antibodies) as provided herein are used together with an agent for determining whether ICOS expression or activity is present, increased, reduced or absent. In alternative embodiments, anti-ICOS antibodies as provided herein are used in the diagnosis and / or treatment of a cancer or a tumor.

The invention discloses application of alpha1-acid glycoprotein in preparation of a medicine for treating lung injury caused by acute pancreatitis, and belongs to the technical field of biological medicine. An acute pancreatitis lung injury model is constructed through ORM1 gene knockout mice, the mice are divided into a normal group, a model group and a treatment group for research, target organ pathological injury degree detection, immunohistochemical analysis and serum inflammatory factor expression quantity are performed after injection administration, and the curative effect difference of the gene knockout mice and wild type mice is compared, so that the acute pancreatitis lung injury model is established. And the treatment effect of the alpha1-acid glycoprotein on the acute pancreatitis lung injury is verified. The invention provides a key basis for research, development and preparation of drugs for treating acute pancreatitis lung injury, and has important clinical application value.

The present invention provides chimeric or recombinant antibodies (Abs) or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins that can specifically bind to human LAG-3 polypeptides, including human LAG-3 polypeptides expressed on the surface of lymphocytes, such as activated T cells that have infiltrated a tumor or tumor infiltrating lymphocytes (TILs); and methods of making and using the same. In alternative embodiments, the chimeric or recombinant antibodies (Abs) or antigen binding fragments thereof, or monomeric or dimeric antigen binding proteins as provided herein are used for in vitro diagnostics by virtue of their ability to specifically bind to activated T cells that have infiltrated a tumor or tumor infiltrating lymphocytes, for example in immunohistochemistry (IHC), for example for the diagnosis and / or treatment of cancer, such as bladder cancer, urothelial cancer, breast cancer, lung cancer, non-small cell lung cancer, kidney cancer, renal clear cell carcinoma, and / or melanoma or malignant melanoma.

The application belongs to the technical field of biology and particularly relates to a recombinant monoclonal antibody variable region coding gene against ATCA2 and a preparation method. The recombinant monoclonal antibody variable region coding gene against ATCA2 comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of the amino acid sequences shown in SEQ ID NO. 6-9; and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO. 10. The application recombines a mouse anti-human ACTA2 recombinant monoclonal antibody by using a hybridoma technology, the recombinant monoclonal antibody has a clear structure, a high titer and better stability, can effectively solve the problems existing in traditional antibody preparation, can be applied to the detection and screening fields such as immunohistochemistry, indirect ELISA, antibody chip preparation and immunofluorescence, and is favorable for obtaining accurate evaluation and detection results.

The application belongs to the technical field of biological medicine, and relates to a BCLAF1 protein Ser564 site phosphorylation antigen peptide, a specific antibody and a preparation method and application thereof. The application identifies BCLAF1 protein Ser564 as a key phosphorylation site through SIK2 kinase screening, and designs and synthesizes a phosphorylation antigen peptide based on the site. After immunizing animals, a polyclonal antibody specifically recognizing BCLAF1 Ser564 site phosphorylation modification is successfully prepared. The antibody has high sensitivity and strong specificity, is suitable for various detection platforms such as immunohistochemistry and immunoblotting, and can be used for evaluating tumor immunotherapy efficacy. The application provides a key tool for analyzing BCLAF1 phosphorylation regulation mechanism, and lays a theoretical foundation for developing an immune combined therapy strategy targeting a SIK2-BCLAF1-CCL5 axis.

A segment of characteristic polypeptide antigen of a TRPV6 protein is selected to immunize mice and then screening is performed to obtain hybridoma cell lines 12CT 9.5.1, 16CT 18.1.1.2 and 16CT 4.1.1.2. The series of cells can secrete monoclonal antibodies against TRPV6 and can specifically recognize the TRPV6 protein and tumour tissue. The series of antibodies can be used to measure the level of TRPV6 in cells in an artificial or automated manner by means of immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), immunofluorescence (IF), chemiluminescent immunoassay (CLIA), turbidimetric immunoassay (TIA), or western blot, are thus used in a method for diagnosing tumour tissue, and relate to the field of biological detection.

The invention provides a preparation method and application of low-pathogenicity avian influenza virus positive serum, and belongs to the technical field of veterinary biological products. The low-pathogenicity avian influenza virus positive serum with high HI titer and neutralizing titer can be obtained by adopting a method of respectively immunizing the live virus and the inactivated vaccine once. The preparation method disclosed by the invention is not limited to the low-pathogenicity avian influenza virus of a single subtype. The positive serum prepared by the method has the characteristics of good specificity, strong sensitivity and the like, and can be used for technical detection of indirect immunofluorescence, western blot, immunohistochemistry and the like; and the kit can also be used for exogenous virus detection of poultry virus live vaccines, separation and identification of clinical viruses, identification and inspection of live vector vaccines, clinical monitoring of avian influenza viruses, epidemiological investigation and immune effect evaluation of related vaccines.

The invention discloses a method for establishing a stage II-III colorectal cancer postoperative recurrence and metastasis prediction model, and belongs to the technical field of biomedicine. The method comprises the following steps: collecting a postoperative tumor tissue sample of a II-III stage colorectal cancer patient, and staining specific immune cells in the colorectal cancer tissue sample by adopting an immunohistochemical technology; and then calculating the average infiltration count of the immune cells, defining a prognostic index according to a specific formula, dividing the II-III stage colorectal cancer patients into a high-risk group and a low-risk group after operation by taking a median of the prognostic index as a cutoff value, and constructing a II-III stage colorectal cancer postoperative recurrence and metastasis prediction model based on the prognostic index. The traditional staging limitation is broken through, the tumor immune microenvironment is focused, specific immune cells are detected, the prognosis index is quantified and constructed, the median of the prognosis index is taken as a truncation value, patients are divided into a high-risk group and a low-risk group, the recurrence and metastasis risk of the high-risk group is large, and the risk of the low-risk group is small. Therefore, a prediction model is constructed, and a doctor is helped to formulate a personalized treatment scheme.

The application discloses application of GPER1 and CD68 as a prognostic marker in preparation of a hepatocarcinoma prognosis test kit. Researches of the application show that by detecting the expression of GPER1 in macrophages of hepatocarcinoma tissues, the survival prognosis of hepatocarcinoma patients can be more accurately predicted. Specifically, a double immunofluorescence staining combined with tyramide signal amplification technology is used to detect the co-expression proportion of GPER1 and CD68 in hepatocarcinoma tissues, and it is shown that the prediction effect of the hepatocarcinoma patients on overall survival and recurrence-free survival is better than the overall GPER1 expression of tumor tissues. Compared with the prior art (only immunohistochemical staining of GPER1 is performed on tumor tissues), the method can obtain more detailed and accurate information of the GPER1 protein expression mode, and the prediction effect on the survival of hepatocarcinoma patients is better; the method is simple and easy to operate, and ordinary technicians can complete the whole operation process.

The application discloses a fluorescently encoded probe and a single-cell immunoblotting method. A nucleic acid tag is disclosed, which comprises oligonucleotide chains f1, f2,..., fn, n>2, each of the oligonucleotide chains containing a fluorescent group and a quenching group, the subsequent oligonucleotide chain being complementary to part of the sequence of the previous oligonucleotide chain, and the quenching group of the subsequent oligonucleotide chain quenching the fluorescent group of the previous oligonucleotide chain. A quenching tag is also disclosed, which comprises a complementary chain capable of being complementary to the oligonucleotide chain in the nucleic acid tag. The application discloses a fluorescently encoded probe comprising the nucleic acid tag and a preparation method of the fluorescently encoded probe, and application of the fluorescently encoded probe in multi-target single-cell immunoblotting technology, immunofluorescence technology and immunohistochemical staining technology. The fluorescently encoded multi-target single-cell immunoblotting method of the application can be used for detecting multi-target proteins by using limited fluorescent channels, has small signal loss and high expansibility.

A method and apparatus for labeling a tissue section is provided. In certain aspects, the methods comprise labeling a tissue sample via a plurality of immunohistochemistry (IHC) assays for detection of markers for characterization of a cancer origin in an individual having a cancer of unknown primary (CUP). The disclosed IHC assays employ chromogen-based detection methods for improved sample efficiency and visualization of biomarkers. Further disclosed is an apparatus for carrying out the disclosed methods.